Skip to main content
. 2021 Jul 5;7:86. doi: 10.1038/s41523-021-00292-y

Fig. 1. CONSORT diagram.

Fig. 1

IBC Invasive breast cancer, NAT neoadjuvant therapy, IBC-NST invasive breast cancer of no special type, ER estrogen receptor, PR progesterone receptor, sTILs stromal tumor-infiltrating lymphocytes.